DeepCure, a Boston, MA-based developing novel, small molecule therapeutics powered by AI and automation of chemistry, raised $24M in Series A-1 funding.
The round was led by IAG Capital Partners (IAG) with participation from current investors.
The company intends to use the funds to further develop its technology, and to advance its immunology and inflammation pipeline towards clinical trials.
Led by CEO Kfir Schreiber, DeepCure was founded by researchers at MIT to accelerate therapies using artificial intelligence (AI) and AI-enabling technologies to innovate small molecule discovery. The company has built a generative AI and physics-based engine to innovate the discovery of small molecule therapies for challenging targets. The engine can map potential interaction sites on the surface of proteins, and design novel, synthesizable molecules with lead-like properties. Additionally, DeepCure has developed an advanced automated chemistry synthesis platform to increase the speed, number, and diversity of molecules that are tested.
FinSMEs
11/04/2024